Author Archive: AZBio

When we all come together, we can do amazing things

Posted on by

“Leading Women – Biotech and Beyond” has gained a reputation as a smart and sassy way to kick off Arizona Biosciences Week. Gathered high in the penthouse boardroom of Perkins Coie, an international law firm, some 40 women – and a few brave men – come together to share support and stories.

“I love to come to this event,” said one attendee. “When smart, savvy and successful woman come together, they are able to be truly authentic. The storytelling and laughter make for exhilarating evening.”Continue reading→

Phoenix embarks on $3B bioscience capital projects, creating 7,000 jobs

Posted on by

“The city of Phoenix has made smart investments into building its bioscience infrastructure and it is paying off in economic impact, new company attraction, exciting job opportunities for residents and most importantly, medical insights that benefit people with health challenges who need help today.” said Joan Koerber-Walker, president and CEO of the Arizona Bioindustry Association.

“One visible example of the impact of these investments is the Phoenix Biomedical Campus, which includes eight facilities and spans 30 acres in the city center. It is a place were we’re training medical professionals, treating patients with life threatening diseases, and creating a home for companies that are working to develop new cures.”Continue reading→

ASU Biodesign Institute executive director urges health care forces to ‘go beyond discovery’ at Arizona Wellbeing Commons conference

Posted on by

With organizations the caliber of Mayo Clinic, TGen, the Flinn Foundation, Arizona BioIndustry Association and the state’s universities, Arizona boasts a multitude of talented scientists, health professionals, life science entrepreneurs, nonprofits and government leaders committed to contributing to the quality of life in our state. Arizona’s bioscience sector is adding jobs at a rate that outpaces the nation. And its public universities are seeing increases in bioscience research funding, expenditures and tech transfer.Continue reading→

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals Inc., combination therapy offers the potential of a safer and more effective approach to a wide variety of cancer treatments

Posted on by

Oncology Pharma is pleased to announce that Kalos Therapeutics’ lead compound, KTH-222, can produce a reduction in the attachment of newly seeded cells to a solid-phase by an average of 39%. These non-clinical results suggest that KTH-222 disrupt tubulin formation and attachment to the solid-phase in a similar way to most of the commonly used tubulin disrupting chemotherapeutic drugs. However, the mechanism of action by KTH-222 may be different than the most commonly used tubulin-disrupting therapies and needs further investigation. Continue reading→